Apotex launches Apo‑Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada

Semaglutide just got a major boost in Canada. Apotex has launched Apo-Semaglutide Injection, a generic version of the well-known research peptide Ozempic. This move opens new doors for researchers who need access to semaglutide, a peptide that’s been making headlines for its effects on metabolism and appetite regulation.

Why does this matter? Researchers know that sourcing quality peptides isn’t always straightforward, especially with branded compounds. A generic option means more labs can run experiments, expand protocols, and compare results with fewer supply headaches. Generic semaglutide could also mean lower costs and less red tape for those working in a research setting.

Key points:

Semaglutide itself is a GLP-1 receptor agonist, studied for its unique effect on glucose metabolism and weight regulation. With more options on the market, expect research to accelerate—whether that’s exploring alternative delivery methods, studying long-term effects, or developing new analytical assays.

For labs looking to source semaglutide, this is a clear signal that the market is shifting. More competition means better access. Check our semaglutide page for details on the peptide itself, or visit the vendor directory to find sourcing options for your next project.

More generic peptide launches like this can only push research forward.